"Poly(ADP-ribose) Polymerases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE.
- Poly(ADP-ribose) Polymerases
- ADP-Ribosyltransferase (Polymerizing)
- Poly(ADP-ribose) Polymerase
- Poly ADP Ribose Polymerase
- Poly ADP Ribose Transferase
- Poly(ADP-Ribose) Transferase
- PARP Polymerase
- Polymerase, PARP
- Poly(ADPribose) Polymerase
- Poly ADP-Ribose Synthase
- Poly ADP Ribose Synthase
- Synthase, Poly ADP-Ribose
- Poly(ADPR) Polymerase
- Poly(ADP-Ribose) Synthase
Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerases".
Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerases".
This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerases" by people in this website by year, and whether "Poly(ADP-ribose) Polymerases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Poly(ADP-ribose) Polymerases" by people in Profiles.
Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239.
PARP inhibition in the ovarian cancer patient: Current approvals and future directions. Pharmacol Ther. 2020 09; 213:107588.
Combination of PARP inhibitor and temozolomide to suppress chordoma progression. J Mol Med (Berl). 2019 08; 97(8):1183-1193.
In vitro effect of microRNA-107 targeting Dkk-1 by regulation of Wnt/?-catenin signaling pathway in osteosarcoma. Medicine (Baltimore). 2017 Jul; 96(27):e7245.
S100B impairs glycolysis via enhanced poly(ADP-ribosyl)ation of glyceraldehyde-3-phosphate dehydrogenase in rodent muscle cells. Am J Physiol Endocrinol Metab. 2017 06 01; 312(6):E471-E481.
Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. Mol Cancer Ther. 2015 Nov; 14(11):2452-62.
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov. 2014 Aug; 4(8):896-904.
The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells. Neoplasia. 2014 Mar; 16(3):257-64, 264.e2.
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6163-72.
ROS-mediated PARP activity undermines mitochondrial function after permeability transition pore opening during myocardial ischemia-reperfusion. J Am Heart Assoc. 2013 Apr 18; 2(2):e000159.